GATA3 cooperates with PARP1 to regulate CCND1 transcription through modulating histone H1 incorporation

Oncogene

Volumn 33, Issue 24, 2014, Pages 3205-3216

  Shan, L ^a   Li, X ^a   Liu, L ^a   Ding, X ^b   Wang, Q ^a   Zheng, Y ^a   Duan, Y ^a   Xuan, C ^a   Wang, Y ^a   Yang, F ^b   Shang, Y ^a   Shi, L ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF BIOPHYSICS   (China)

Author keywords

breast cancer; cell proliferation; gene transcription

Indexed keywords

CYCLIN D1; HISTONE H1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; TRANSCRIPTION FACTOR GATA 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER CELL LINE; BREAST CARCINOGENESIS; CELL PROLIFERATION; CHROMATIN; CONTROLLED STUDY; EMBRYO; ENZYME MODIFICATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSACTIVATION; TRANSCRIPTION REGULATION;

ANIMALS; APOPTOSIS; BASE SEQUENCE; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CHROMATIN IMMUNOPRECIPITATION; CYCLIN D1; FEMALE; FLOW CYTOMETRY; GATA3 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; IMMUNOPRECIPITATION; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; POLY(ADP-RIBOSE) POLYMERASES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEQUENCE HOMOLOGY, NUCLEIC ACID; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902457300     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.270     Document Type: Article

References (58)

1. Patient RK, McGhee JD. The GATA family (vertebrates and invertebrates). Curr Opin Genet Dev 2002; 12: 416-422.
2. Hoene V, Fischer M, Ivanova A, Wallach T, Berthold F, Dame C. GATA factors in human neuroblastoma: distinctive expression patterns in clinical subtypes. Br J Cancer 2009; 101: 1481-1489.
3. Tsarovina K, Pattyn A, Stubbusch J, Muller F, van der Wees J, Schneider C et al. Essential role of GATA transcription factors in sympathetic neuron development. Development 2004; 131: 4775-4786.
4. Imagawa S, Yamamoto M, Miura Y. Negative regulation of the erythropoietin gene expression by the GATA transcription factors. Blood 1997; 89: 1430-1439.
5. Zhang C, Ye X, Zhang H, Ding M, Deng H. GATA factors induce mouse embryonic stem cell differentiation toward extraembryonic endoderm. Stem Cells Dev 2007; 16: 605-613.
6. Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 1997; 89: 587-596.
7. Taghon T, Yui MA, Rothenberg EV. Mast cell lineage diversion of T lineage precursors by the essential T cell transcription factor GATA-3. Nat Immunol 2007; 8: 845-855.
8. Ho IC, Tai TS, Pai SY. GATA3 and the T-cell lineage: essential functions before and after T-helper-2-cell differentiation. Nat Rev Immunol 2009; 9: 125-135.
9. Ting CN, Olson MC, Barton KP, Leiden JM. Transcription factor GATA-3 is required for development of the T-cell lineage. Nature 1996; 384: 474-478.
10. Kouros-Mehr H, Slorach EM, Sternlicht MD, Werb Z. GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell 2006; 127: 1041-1055.
11. Kouros-Mehr H, Kim JW, Bechis SK, Werb Z. GATA-3 and the regulation of the mammary luminal cell fate. Curr Opin Cell Biol 2008; 20: 164-170.
12. Asselin-Labat ML, Sutherland KD, Barker H, Thomas R, Shackleton M, Forrest NC et al. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol 2007; 9: 201-209.
13. Zheng R, Blobel GA. GATA transcription factors and cancer. Genes Cancer 2010; 1: 1178-1188.
14. Mehra R, Varambally S, Ding L, Shen R, Sabel MS, Ghosh D, et al. Identification of GATA3 as a breast cancer prognostic marker by global gene expression metaanalysis. Cancer Res 2005; 65: 11259-11264.
15. Ciocca V, Daskalakis C, Ciocca RM, Ruiz-Orrico A, Palazzo JP. The significance of GATA3 expression in breast cancer: a 10-year follow-up study. Human Pathol 2009; 40: 489-495.
16. Yoon NK, Maresh EL, Shen D, Elshimali Y, Apple S, Horvath S, et al. Higher levels of GATA3 predict better survival in women with breast cancer. Human Pathol 2010; 41: 1794-1801.
17. Hoch RV, Thompson DA, Baker RJ, Weigel RJ. GATA-3 is expressed in association with estrogen receptor in breast cancer. Int J Cancer 1999; 84: 122-128.
18. Parikh P, Palazzo JP, Rose LJ, Daskalakis C, Weigel RJ. GATA-3 expression as a predictor of hormone response in breast cancer. J Am Collf Surg 2005; 200: 705-710.
19. Wilson BJ, Giguere V. Meta-analysis of human cancer microarrays reveals GATA3 is integral to the estrogen receptor alpha pathway. Mol Cancer 2008; 7: 49.
20. Kouros-Mehr H, Bechis SK, Slorach EM, Littlepage LE, Egeblad M, Ewald AJ et al. GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell 2008; 13: 141-152.
21. Yan W, Cao QJ, Arenas RB, Bentley B, Shao R. GATA3 inhibits breast cancer metastasis through the reversal of epithelial-mesenchymal transition. J Biol Chem 2010; 285: 14042-14051.
22. Tkocz D, Crawford NT, Buckley NE, Berry FB, Kennedy RD, Gorski JJ et al. BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers. Oncogene 2011; 31(32): 3667-3678.
23. Eeckhoute J, Keeton EK, Lupien M, Krum SA, Carroll JS, Brown M. Positive crossregulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer. Cancer Res 2007; 67: 6477-6483.
24. Rosenfeld MG, Lunyak VV, Glass CK. Sensors and signals: a coactivator/corepressor/ epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev 2006; 20: 1405-1428.
25. Xu L, Glass CK, Rosenfeld MG. Coactivator and corepressor complexes in nuclear receptor function. Curr Opin Genet Dev 1999; 9: 140-147.
26. Kurokawa R, Rosenfeld MG, Glass CK. Transcriptional regulation through noncoding RNAs and epigenetic modifications. RNA Biol 2009; 6: 233-236.
27. Wolffe AP, Guschin D. Review: chromatin structural features and targets that regulate transcription. J Struct Biol 2000; 129: 102-122.
28. Hwang SS, Lee S, Lee W, Lee GR. GATA-binding protein-3 regulates T helper typ. 2 cytokine and ifng loci through interaction with metastasis-associated protein 2. Immunology 2010; 131: 50-58.
29. Blokzijl A, ten Dijke P, Ibanez CF. Physical and functional interaction between GATA-3 and Smad3 allows TGF-beta regulation of GATA target genes. Curr Biol 2002; 12: 35-45.
30. Wei G, Abraham BJ, Yagi R, Jothi R, Cui K, Sharma S et al. Genome-wide analyses of transcription factor GATA3-mediated gene regulation in distinct T cell types. Immunity 2011; 35: 299-311.
31. Kim MY, Mauro S, Gevry N, Lis JT, Kraus WL. NAD-dependent modulation of chromatin structure and transcription by nucleosome binding properties of PARP-1. Cell 2004; 119: 803-814.
32. Mao Z, Hine C, Tian X, Van Meter M, Au M, Vaidya A et al. SIRT6 promotes DNA repair under stress by activating PARP1. Science 2011; 332: 1443-1446.
33. Bouchard VJ, Rouleau M, Poirier GG. PARP-1, a determinant of cell survival in response to DNA damage. Exp Hematol 2003; 31: 446-454.
34. Huber A, Bai P, de Murcia JM, de Murcia G. PARP-1, PARP-2 and ATM in the DNA damage response: functional synergy in mouse development. DNA Repair 2004; 3: 1103-1108.
35. Krishnakumar R, Kraus WL. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol Cell 2010; 39: 8-24.
36. Krishnakumar R, Kraus WL. PARP-1 regulates chromatin structure and transcription through a KDM5B-dependent pathway. Mol Cell 2010; 39: 736-749.
37. Lonn P, van der Heide LP, Dahl M, Hellman U, Heldin CH, Moustakas A. PARP-1 attenuates Smad-mediated transcription. Mol Cell 2010; 40: 521-532.
38. Kraus WL. Transcriptional control by PARP-1: chromatin modulation, enhancer-binding, coregulation, and insulation. Curr Opin Cell Biol 2008; 20: 294-302.
39. Arnold A, Papanikolaou A. Cyclin D1 in breast cancer pathogenesis. J Clin Oncol 2005; 23: 4215-4224.
40. Bartkova J, Lukas J, Muller H, Lutzhoft D, Strauss M, Bartek J. Cyclin D1 protein expression and function in human breast cancer. International journal of cancer. J Int Cancer 1994; 57: 353-361.
41. Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C et al. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 1994; 54: 1812-1817.
42. Fantl V, Smith R, Brookes S, Dickson C, Peters G. Chromosome 11q13 abnormalities in human breast cancer. Cancer Surveys 1993; 18: 77-94.
43. Cipak L, Jantova S. PARP-1 inhibitors: a novel genetically specific agents for cancer therapy. Neoplasma 2010; 57: 401-405.
44. Tulin A. Re-evaluating PARP1 inhibitor in cancer. Nat Biotechnol 2011; 29: 1078-1079.
45. Ossovskaya V, Koo IC, Kaldjian EP, Alvares C, Sherman BM. Upregulation of poly (ADP-ribose) polymerase-1 (PARP1) in triple-negative breast cancer and other primary human tumor types. Genes Cancer 2010; 1: 812-821.
46. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 2000; 103: 843-852.
47. Zhang H, Yi X, Sun X, Yin N, Shi B, Wu H et al. Differential gene regulation by the SRC family of coactivators. Genes Dev 2004; 18: 1753-1765.
48. Wang Y, Zhang H, Chen Y, Sun Y, Yang F, Yu W et al. LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell 2009; 138: 660-672.
49. Krishnakumar R, Gamble MJ, Frizzell KM, Berrocal JG, Kininis M, Kraus WL. Reciprocal binding of PARP-1 and histone H1 at promoters specifies transcriptional outcomes. Science 2008; 319: 819-821.
50. Ewen ME, Lamb J. The activities of cyclin D1 that drive tumorigenesis. Trends Mol Med 2004; 10: 158-162.
51. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994; 369: 669-671.
52. Aguilar-Quesada R, Munoz-Gamez JA, Martin-Oliva D, Peralta-Leal A, Quiles-Perez R, Rodriguez-Vargas JM et al. Modulation of transcription by PARP-1: consequences in carcinogenesis and inflammation. Curr Med Chem 2007; 14: 1179-1187.
53. Simsek D, Brunet E, Wong SY, Katyal S, Gao Y, McKinnon PJ et al. DNA ligase III promotes alternative nonhomologous end-joining during chromosomal translocation formation. PLoS Genet 2011; 7: e1002080.
54. Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell 2010; 40: 179-204.
55. Haffner MC, De Marzo AM, Meeker AK, Nelson WG, Yegnasubramanian S. Transcription- induced DNA double strand breaks: both oncogenic force and potential therapeutic target? Clin Cancer Res 2011; 17: 3858-3864.
56. Ju BG, Lunyak VV, Perissi V, Garcia-Bassets I, Rose DW, Glass CK et al. A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription. Science 2006; 312: 1798-1802.
57. Rojo F, Garcia-Parra J, Zazo S, Tusquets I, Ferrer-Lozano J, Menendez S et al. Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer. Ann Oncol 2012; 23: 1156-1164.
58. Li R, Zhang H, Yu W, Chen Y, Gui B, Liang J et al. ZIP: a novel transcription repressor, represses EGFR oncogene and suppresses breast carcinogenesis. EMBO J 2009; 28: 2763-2776.